Affimed’s (AFMD) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Affimed (NASDAQ:AFMD) in a research note released on Tuesday,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock.

AFMD has been the subject of a number of other research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Stifel Nicolaus decreased their target price on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat, Affimed currently has an average rating of “Moderate Buy” and an average price target of $16.00.

Affimed Stock Down 2.9 %

AFMD stock opened at $2.32 on Tuesday. Affimed has a one year low of $2.19 and a one year high of $8.95. The firm has a 50-day moving average of $3.15 and a two-hundred day moving average of $4.21. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13.

Hedge Funds Weigh In On Affimed

Hedge funds have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in shares of Affimed during the 3rd quarter worth about $44,000. Choreo LLC acquired a new stake in Affimed in the 2nd quarter worth approximately $54,000. FMR LLC boosted its position in Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares during the period. Intellectus Partners LLC grew its holdings in Affimed by 12.2% during the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its position in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares during the period. 30.82% of the stock is owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.